What is the recommended systemic therapy for diffuse large B‑cell lymphoma (DLBCL) with cardiac involvement, and how should treatment be modified based on cardiac function?

DLBCL with Cardiac Involvement: Treatment Recommendations

Primary Recommendation

For DLBCL with cardiac involvement, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard treatment, with modifications based on cardiac function: patients with preserved cardiac function (LVEF >50%) should receive standard R-CHOP, while those with reduced cardiac function (LVEF 40-50%) should receive anthracycline-containing regimens with cardioprotective modifications such as liposomal doxorubicin substitution or continuous infusion, and patients with severe cardiac dysfunction (LVEF <40%) should receive non-anthracycline regimens or anthracycline omission. 1, 2, 3

Treatment Algorithm by Cardiac Function

Preserved Cardiac Function (LVEF >50%)

• Standard R-CHOP21 × 6-8 cycles is the established treatment 1
• Age 60-80 years: 6-8 cycles R-CHOP with 8 doses rituximab 1
• Age >80 years (fit): R-miniCHOP with dose attenuation 1
• Close cardiac monitoring with ECG, echocardiography, and BNP levels before each cycle 2, 3

Moderately Reduced Function (LVEF 40-50%)

Three modification strategies exist with variable provider preference 4:

1. Liposomal doxorubicin substitution (26% provider preference): Replace conventional doxorubicin with non-pegylated liposomal doxorubicin in R-CHOP regimen 4, 5

   • Reduces cardiotoxicity risk while maintaining anthracycline benefit
   • Data shows fewer LVEF drops below 50% (4.6% vs 15.8%) with liposomal formulation 5

2. Continuous doxorubicin infusion (12% provider preference): R-EPOCH regimen 4, 6

   • Theoretical reduction in cardiotoxicity through continuous infusion
   • May reduce perforation risk in cardiac masses 6

3. Non-anthracycline regimens (30% provider preference): R-CEOD (rituximab, cyclophosphamide, pirarubicin, etoposide) or gemcitabine-based alternatives 4, 2

Severe Cardiac Dysfunction (LVEF <40%)

• Omit or substitute doxorubicin from the outset 1
• Consider gemcitabine, etoposide, or complete anthracycline omission 1
• Alternative: R-CEOD regimen as demonstrated in cardiac metastasis case achieving partial response 2

Cardiac-Specific Considerations

Tumor Location and ECG Manifestations

ECG patterns correlate with anatomical involvement and guide arrhythmia management 3:

• Right atrial involvement: Atrial tachycardia or atrial fibrillation
• Pericardial infiltration: Low-voltage QRS, electrical alternans with massive effusion
• Myocardial infiltration: Ventricular tachycardia, high-grade AV block risk
• Coronary sinus involvement: Requires careful monitoring for conduction abnormalities 6

Mandatory Cardiac Monitoring Protocol

Before each treatment cycle assess 2, 3:

• Echocardiography for LVEF measurement
• Electrocardiogram for rhythm and conduction abnormalities
• Brain natriuretic peptide (BNP) or NT-proBNP levels
• NT-proBNP >400 pg/ml indicates increased cardiac stress 5

Anti-arrhythmic and Cardioprotective Integration

Concurrent cardioprotective therapy improves chemotherapy tolerance 3:

• Anti-arrhythmic medications for documented arrhythmias
• Successful arrhythmia control correlates with improved clinical outcomes 3
• Cardiology co-management is essential for patients with cardiac involvement

Critical Pitfalls and Caveats

The Anthracycline Dilemma

There is substantial practice variability (70% of providers modify treatment) with no consensus on optimal approach 4. The tension exists between:

• Oncologic efficacy: Anthracyclines remain preferred for DLBCL cure rates 2
• Cardiac safety: Risk of perforation, arrhythmias, and heart failure in cardiac masses 3, 6

The evidence suggests anthracycline-containing regimens should be used whenever cardiac function permits, as complete omission may compromise cure rates 2.

Monitoring Gaps

Only 32% of providers order post-treatment echocardiograms after anthracycline exposure 4, representing a significant surveillance gap given late cardiotoxicity risks.

Disease-Specific Urgency

DLBCL with cardiac involvement is life-threatening 2, 7:

• Rapid progression with risk of cardiac rupture or arrest
• Arrhythmias and conduction disturbances are common complications 3, 7
• Early recognition and immediate treatment initiation are critical

Age-Specific Modifications

Elderly Patients (>80 years)

• R-miniCHOP for fit patients 1
• Consider anthracycline substitution or omission earlier in treatment course 1
• Comprehensive geriatric assessment guides treatment intensity 1

Younger High-Risk Patients (aa-IPI ≥2)

• Standard R-CHOP21 × 6-8 cycles unless cardiac contraindications 1
• Clinical trial enrollment should be priority 1
• R-ACVBP or R-CHOEP alternatives not directly compared but frequently used 1

Relapsed/Refractory Disease with Cardiac History

For patients with cardiac involvement who relapse:

• Early relapse (<12 months): CAR T-cell therapy preferred 8, 9
• Late relapse (>12 months): Salvage chemotherapy followed by autologous stem cell transplant 8, 9
• Post-CAR T progression: Bispecific antibodies or antibody-drug conjugate combinations 8, 9

The cardiac history necessitates careful selection of salvage regimens avoiding additional anthracycline exposure.